Table of Contents
<< Previous Issue | Nov 2013 (Vol: 2013, Issue: 11) | Next Issue >> |
- Section: Licensing
-
Pfizer Mitigates Tanezumab Risk with Potential US$1.8 B Deal with Eli Lilly
-
Roche Signals Return to Antibiotics Development with Polyphor Licensing Deal
- Section: Mergers & Acquisitions
-
Endo Looks to Geographic Expansion and Tax Advantages with US$1.6 B Paladin Buyout
-
Salix Adds to Gastroenterology Franchise with US$2.6 B Santarus Acquisition
-
Shire Progresses Rare Disease Strategy with US$4.2 B ViroPharma Purchase